For research use only. Not for therapeutic Use.
Pimecrolimus is an immunomodulating agent used in the treatment of atopic dermatitis (eczema). It is currently available as a topical cream, once marketed by Novartis (however Galderma is promoting the compound in Canada since early 2007) under the trade name Elidel. Pimecrolimus is an ascomycin macrolactam derivative. It has been shown in vitro that pimecrolimus binds to macrophilin-12(also referred to as FKBP-12) and inhibits calcineurin. Thus pimecrolimus inhibits T-cell activation by inhibiting the synthesis and release of cytokines from T-cells. Pimecrolimus also prevents the release of inflammatory cytokines and mediators from mast cells.
| Catalog Number | A000429 |
| CAS Number | 137071-32-0 |
| Synonyms | Elidel; 137071-32-0; Pimecrolimus(Elidel); SDZ ASM 981; SDZ-ASM-981 |
| Molecular Formula | C₄₃H₆₈ClNO₁₁ |
| Purity | ≥95% |
| Storage | -20°C |
| InChI | InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18-,2 |
| InChIKey | KASDHRXLYQOAKZ-OLHLVPFQSA-N |
| SMILES | CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)Cl)C)O)C)OC)OC)C)C |
| Reference | 1: Sigurgeirsson B, Luger T. A 5-year randomized trial on the safety and efficacy 2: Weidinger S, Baurecht H, Schmitt J. A 5-year randomized trial on the safety <br> <br> 5: Xu P, Chen J, Tan C, Lai RS, Min ZS. Pimecrolimus increases the melanogenesis 6: Malachowski SJ, Creasey M, Kinkley N, Heaphy MR Jr. Annular Lichenoid 7: Hussner J, Sünwoldt J, Seibert I, Gliesche DG, Zu Schwabedissen HE. 8: Poddighe D, Brazzelli V, Licari A, Marseglia GL. Acute Pustular Dermatosis, 9: Yingfang F, Zhuang B, Wang C, Xu X, Xu W, Lv Z. Pimecrolimus micelle exhibits <br> |
